FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1595368274> ?p ?o ?g. }

• W1595368274 endingPage "5277" @default.
• W1595368274 startingPage "5270" @default.
• W1595368274 abstract "BACKGROUND: Plasmablastic lymphoma (PBL) is a rare and aggressive B-cell lymphoma strongly associated with human immunodeficiency virus (HIV) infection. The authors conducted a multi-institutional, retrospective study to describe characteristics and determine prognostic factors in HIV-associated PBL. METHODS: For this study, the investigators included consecutive, HIV-positive patients diagnosed between the years 2000 and 2010 whose tumors had a plasmablastic morphology, were cluster of differentiation 20 (CD20)-negative, and expressed markers of plasmacytic differentiation. RESULTS: Fifty patients from 13 institutions were evaluated. The median age was 43 years, and there was a male predominance. The median count of cells that were positive for CD4 (a glycoprotein expressed on the surface of T-helper cells, monocytes, macrophages, and dendritic cells) was 206 cells/mm3. At presentation, 90% of patients had extranodal involvement, 69% presented with advanced stage disease, and 27% had oral involvement. Rearrangements of v-myc myelocytomatosis viral oncogene homolog (MYC) were detected in 41% of the tested patients. Eighty-five percent of patients received chemotherapy, with 63% receiving cyclophosphamide, doxorubicin, vincristine, and prednisone and 37% receiving more intensive regimens. The complete response (CR) rate was 66%. The median overall survival (OS) was 11 months regardless of the intensity of chemotherapy. In the survival analysis, an Eastern Cooperative Oncology Group performance status ≥2, advanced stage, and MYC rearrangements were associated significantly with a worse outcome, whereas attaining a CR with chemotherapy was associated with a better outcome. CONCLUSIONS: The prognosis of PBL in HIV-infected individuals remains poor in the highly active antiretroviral therapy era. Intensive chemotherapy regimens do not seem to increase survival in patients with HIV-associated PBL. Cancer 2012. © 2012 American Cancer Society." @default.
• W1595368274 created "2016-06-24" @default.
• W1595368274 creator A5002404022 @default.
• W1595368274 creator A5003780767 @default.
• W1595368274 creator A5008706897 @default.
• W1595368274 creator A5012895760 @default.
• W1595368274 creator A5020063141 @default.
• W1595368274 creator A5024726033 @default.
• W1595368274 creator A5035795106 @default.
• W1595368274 creator A5044226126 @default.
• W1595368274 creator A5046908926 @default.
• W1595368274 creator A5058311223 @default.
• W1595368274 creator A5062138355 @default.
• W1595368274 creator A5063643387 @default.
• W1595368274 creator A5070460361 @default.
• W1595368274 creator A5080373697 @default.
• W1595368274 date "2012-04-17" @default.
• W1595368274 modified "2023-10-16" @default.
• W1595368274 title "Human immunodeficiency virus-associated plasmablastic lymphoma" @default.
• W1595368274 cites W188036732 @default.
• W1595368274 cites W1934174175 @default.
• W1595368274 cites W1978932947 @default.
• W1595368274 cites W1981889346 @default.
• W1595368274 cites W1982470026 @default.
• W1595368274 cites W1988703453 @default.
• W1595368274 cites W1995926405 @default.
• W1595368274 cites W2022357538 @default.
• W1595368274 cites W2027698567 @default.
• W1595368274 cites W2029103839 @default.
• W1595368274 cites W2047053241 @default.
• W1595368274 cites W2060413939 @default.
• W1595368274 cites W2067578715 @default.
• W1595368274 cites W2078256076 @default.
• W1595368274 cites W2089665062 @default.
• W1595368274 cites W2101551355 @default.
• W1595368274 cites W2109806588 @default.
• W1595368274 cites W2111899617 @default.
• W1595368274 cites W2127842142 @default.
• W1595368274 cites W2130144934 @default.
• W1595368274 cites W2133201432 @default.
• W1595368274 cites W2137216850 @default.
• W1595368274 cites W2143352679 @default.
• W1595368274 cites W2148237316 @default.
• W1595368274 cites W2156984457 @default.
• W1595368274 cites W2170304875 @default.
• W1595368274 doi "https://doi.org/10.1002/cncr.27551" @default.
• W1595368274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22510767" @default.
• W1595368274 hasPublicationYear "2012" @default.
• W1595368274 type Work @default.
• W1595368274 sameAs 1595368274 @default.
• W1595368274 citedByCount "136" @default.
• W1595368274 countsByYear W15953682742013 @default.
• W1595368274 countsByYear W15953682742014 @default.
• W1595368274 countsByYear W15953682742015 @default.
• W1595368274 countsByYear W15953682742016 @default.
• W1595368274 countsByYear W15953682742017 @default.
• W1595368274 countsByYear W15953682742018 @default.
• W1595368274 countsByYear W15953682742019 @default.
• W1595368274 countsByYear W15953682742020 @default.
• W1595368274 countsByYear W15953682742021 @default.
• W1595368274 countsByYear W15953682742022 @default.
• W1595368274 countsByYear W15953682742023 @default.
• W1595368274 crossrefType "journal-article" @default.
• W1595368274 hasAuthorship W1595368274A5002404022 @default.
• W1595368274 hasAuthorship W1595368274A5003780767 @default.
• W1595368274 hasAuthorship W1595368274A5008706897 @default.
• W1595368274 hasAuthorship W1595368274A5012895760 @default.
• W1595368274 hasAuthorship W1595368274A5020063141 @default.
• W1595368274 hasAuthorship W1595368274A5024726033 @default.
• W1595368274 hasAuthorship W1595368274A5035795106 @default.
• W1595368274 hasAuthorship W1595368274A5044226126 @default.
• W1595368274 hasAuthorship W1595368274A5046908926 @default.
• W1595368274 hasAuthorship W1595368274A5058311223 @default.
• W1595368274 hasAuthorship W1595368274A5062138355 @default.
• W1595368274 hasAuthorship W1595368274A5063643387 @default.
• W1595368274 hasAuthorship W1595368274A5070460361 @default.
• W1595368274 hasAuthorship W1595368274A5080373697 @default.
• W1595368274 hasConcept C126322002 @default.
• W1595368274 hasConcept C143998085 @default.
• W1595368274 hasConcept C203014093 @default.
• W1595368274 hasConcept C2776694085 @default.
• W1595368274 hasConcept C2776755627 @default.
• W1595368274 hasConcept C2779338263 @default.
• W1595368274 hasConcept C2779429289 @default.
• W1595368274 hasConcept C2779725641 @default.
• W1595368274 hasConcept C2781166303 @default.
• W1595368274 hasConcept C71924100 @default.
• W1595368274 hasConcept C90924648 @default.
• W1595368274 hasConceptScore W1595368274C126322002 @default.
• W1595368274 hasConceptScore W1595368274C143998085 @default.
• W1595368274 hasConceptScore W1595368274C203014093 @default.
• W1595368274 hasConceptScore W1595368274C2776694085 @default.
• W1595368274 hasConceptScore W1595368274C2776755627 @default.
• W1595368274 hasConceptScore W1595368274C2779338263 @default.
• W1595368274 hasConceptScore W1595368274C2779429289 @default.
• W1595368274 hasConceptScore W1595368274C2779725641 @default.
• W1595368274 hasConceptScore W1595368274C2781166303 @default.
• W1595368274 hasConceptScore W1595368274C71924100 @default.

• next